Tyra Biosciences sees 5.8% stake by Paradigm

Paradigm BioCapital-affiliated entities and Senai Asefaw disclose over 5% beneficial ownership stakes in Tyra Biosciences common stock.

Rhea-AI Filing Summary

Tyra Biosciences, Inc. (TYRA) is reported to have a significant shareholder group led by Paradigm BioCapital. Paradigm BioCapital Advisors LP, its general partner Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each report beneficial ownership of 3,473,453 shares of Tyra common stock, representing 5.8% of the outstanding shares. Paradigm BioCapital International Fund Ltd. separately reports 3,060,595 shares, or 5.1%. These positions are based on 59,676,939 shares of common stock outstanding as of July 31, 2026. The Fund and one or more separately managed accounts managed by Paradigm BioCapital Advisors LP directly hold the shares, and the other reporting persons may be deemed to share beneficial ownership through their roles in the advisory structure, while each disclaims ownership beyond securities directly held.

Key Figures

Shares beneficially owned (Adviser / Adviser GP / Senai Asefaw): 3,473,453 shares Ownership percentage (Adviser / Adviser GP / Senai Asefaw): 5.8% Shares beneficially owned (Paradigm BioCapital International Fund Ltd.): 3,060,595 shares +4 more

7 metrics

Shares beneficially owned (Adviser / Adviser GP / Senai Asefaw) 3,473,453 shares Beneficial ownership in Tyra Biosciences common stock as of September 10, 2026

Ownership percentage (Adviser / Adviser GP / Senai Asefaw) 5.8% Portion of Tyra Biosciences common stock outstanding based on 59,676,939 shares

Shares beneficially owned (Paradigm BioCapital International Fund Ltd.) 3,060,595 shares Fund’s beneficial ownership in Tyra Biosciences common stock as of September 10, 2026

Ownership percentage (Paradigm BioCapital International Fund Ltd.) 5.1% Portion of Tyra Biosciences common stock outstanding based on 59,676,939 shares

Shares outstanding 59,676,939 shares Tyra Biosciences common stock outstanding as of July 31, 2026

Par value per share $0.0001 per share Tyra Biosciences common stock par value

Date of Event September 10, 2026 Date requiring the Schedule 13G filing for Tyra Biosciences

Key Terms

beneficial ownership, dispositive power, Schedule 13G, CUSIP Number, +1 more

5 terms

beneficial ownership financial

"The percentages of beneficial ownership contained herein are based on 59,676,939 shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

dispositive power financial

"Sole Dispositive Power 3,473,453.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

"The percentages of beneficial ownership contained herein are based on 59,676,939 shares of Common Stock outstanding"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

CUSIP Number financial

"CUSIP Number(s): 90240B106"

A CUSIP number is a nine-character code that uniquely identifies a specific U.S. or Canadian stock, bond, or other security, similar to a barcode or a social-security number for a financial instrument. It matters to investors because it removes confusion between similar securities, ensures trades and settlements are applied to the correct issue, and helps locate official documents and transaction records quickly.

joint filing agreement regulatory

"Exhibit 99.1 - Joint Filing Agreement"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What percentage of Tyra Biosciences (TYRA) shares does Paradigm BioCapital report owning?

Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, and Senai Asefaw, M.D. each report beneficial ownership of 3,473,453 shares of Tyra Biosciences common stock, representing 5.8% of the outstanding shares based on 59,676,939 shares outstanding as of July 31, 2026.

How many Tyra Biosciences (TYRA) shares does Paradigm BioCapital International Fund Ltd. hold?

Paradigm BioCapital International Fund Ltd. reports 3,060,595 shares of Tyra Biosciences common stock, representing 5.1% of the company’s outstanding shares, calculated using 59,676,939 shares outstanding as of July 31, 2026.

What is the total Tyra Biosciences (TYRA) share count used in this Schedule 13G?

The beneficial ownership percentages in this Schedule 13G are calculated using 59,676,939 shares of Tyra Biosciences common stock outstanding as of July 31, 2026, as reported by the company in its Form 10-Q filed on August 4, 2026.

Who are the reporting persons in this Tyra Biosciences (TYRA) Schedule 13G?

The reporting persons are Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd. They report beneficial ownership of Tyra Biosciences common stock through a fund and separately managed accounts.

What type of security in Tyra Biosciences (TYRA) is reported in this Schedule 13G?

The filing reports beneficial ownership of Tyra Biosciences’ Common Stock, $0.0001 par value per share, which has the CUSIP 90240B106.

As of what date is the beneficial ownership of Tyra Biosciences (TYRA) reported?

The beneficial ownership information is stated as of the close of business on September 10, 2026, which is the Date of Event requiring the Schedule 13G filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/17/2026 - 04:07 PM Accepted by SEC EDGAR 09/17/2026 - 04:06 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Tyra Biosciences, Inc.

(Name of Issuer)

Common Stock, $0.0001 par value per share

(Title of Class of Securities)

90240B106

(CUSIP Number)

09/10/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Paradigm BioCapital Advisors LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,473,453.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,473,453.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,473,453.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Paradigm BioCapital Advisors GP LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,473,453.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,473,453.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,473,453.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

OO

Comment for Type of Reporting Person: limited liability company

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Senai Asefaw, M.D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,473,453.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,473,453.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,473,453.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

CUSIP Number(s): 90240B106

1

Names of Reporting Persons

Paradigm BioCapital International Fund Ltd.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,060,595.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,060,595.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,060,595.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.1 %

12

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Tyra Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 2656 State Street, Carlsbad, CA 92008
Item 2.
(a)	Name of person filing: This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person.
(b)	Address or principal business office or, if none, residence: The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 520 Fifth Avenue, 23rd Floor, New York, NY 10036.
(c)	Citizenship: For citizenship or place of organization see Item 4 of the cover page of each Reporting Person.
(d)	Title of class of securities: Common Stock, $0.0001 par value per share
(e)	CUSIP Number(s): 90240B106
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on September 10, 2026, the Date of Event which requires the filing of this Schedule 13G.
(b)	Percent of class: See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 59,676,939 shares of Common Stock outstanding as of July 31, 2026, as reported by the Issuer in its Form 10-Q filed with the SEC on August 4, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 on the cover page for each Reporting Person.
	(ii) Shared power to vote or to direct the vote: See Item 6 on the cover page for each Reporting Person.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 on the cover page for each Reporting Person.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 on the cover page for each Reporting Person.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Paradigm BioCapital Advisors LP

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	09/17/2026

Paradigm BioCapital Advisors GP LLC

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	09/17/2026

Senai Asefaw, M.D.

Signature:	/s/ Senai Asefaw, M.D.
Name/Title:	N/A
Date:	09/17/2026

Paradigm BioCapital International Fund Ltd.

Signature:	/s/ David K. Kim
Name/Title:	David K. Kim / Authorized Signatory
Date:	09/17/2026

Exhibit Information

Exhibit 99.1 - Joint Filing Agreement